While estrogen action is the major driver of uterine development, androgens acting via the androgen receptor (AR) may also promote uterine growth as suggested by uterine phenotypes in global AR knockout (ARKO) female mice. Because AR is expressed in uterine endometrial glands, we generated (Cre/loxP) uterine gland epithelium-specific ARKO (ugeARKO) to determine the role of endometrial gland-specific androgen actions. However, AR in uterine gland epithelium may not be required for normal uterine development and function because ugeARKO females had normal uterine development and fertility. To determine if exogenous androgens acting via AR can fully support uterine growth in the absence of estrogens, the ARKO and ugeARKO females were ovariectomized and treated with supraphysiological doses of testosterone or dihydrotestosterone (nonaromatizable androgen). Both dihydrotestosterone and testosterone supported full uterine regrowth in wild-type females while ARKO females had no regrowth (comparable to ovariectomized only). These findings suggest that androgens acting via AR can promote full uterine regrowth in the absence of estrogens. The ugeARKO had 50% regrowth when compared to intact uterine glands, and histomorphologically, both the endometrial and myometrial areas were significantly (P , 0.05) reduced, suggesting glandular epithelial AR located in the endometrium may indirectly modify myometrial development. Additionally, to confirm Cre function in endometrial glands, we generated uge-specific PTEN knockout mouse model. The ugePTEN knockout females developed severe endometrial hyperplasia and therefore present a novel model for future research.
INTRODUCTION
Androgens are 19-carbon steroid hormones that mediate their effects via androgen receptor (AR). AR is encoded by an X chromosomal gene and belongs to the nuclear receptor superfamily [1] . It is expressed in target organs, including the uterus of both rodents [2, 3] and humans [4, 5] , being detected in the luminal and glandular epithelial and stromal cells in endometrium as well as myometrial cells of the human uterus [4, 5] . Similarly in the mouse uterus, Ar mRNA is expressed in the luminal and glandular epithelial cells, stromal cells, and smooth muscle cells [2] , and the intensity of Ar mRNA labeling is quite uniform throughout the different uterine compartments. The biological effects of androgens in male physiology are well known, but their physiological roles in the female beyond being the obligate precursors for conversion to estrogens by aromatase [6] have only recently been recognized [7] .
Androgens have growth-and differentiation-promoting actions in the rodent uterus [8] [9] [10] [11] . Already in the 1970s, it was demonstrated that administration of androgens (testosterone or nonaromatizable dihydrotestosterone [DHT] ) to immature hypophysectomized rats significantly increased uterine weights [8, 9] . In addition, the global AR knockout (ARKO) female mice have thinner uterine wall and reduced total uterine area compared to the wild-type (WT) controls [11] , suggesting the growth-promoting role of androgens in uterus is mediated via the AR. Hence, these in vivo studies collectively suggest a uterine growth-promoting function of androgens that acts via AR. However, in contradiction, the aromatizable proandrogen, androstenedione, was shown to inhibit the proliferation of human endometrial epithelial cells, an effect that was reversed by an antiandrogen (cyproterone acetate), indicating local, uterine cell-specific AR-mediated actions may also inhibit uterine growth [12] . Furthermore, a role of androgens in clinical uterine cancers has been proposed [13] .
Androgens also have a role in optimal female fertility because androgen-insensitive ARKO female mice produce significantly fewer pups compared to the WT females in mating experiments [7] . Glandular epithelial cells in the uterine endometrium synthesize, secrete, and transport proteins and related substances that nourish the developing embryo [14] [15] [16] , and these secretions are vital for the survival and development of embryos [17] . Therefore, successful morphogenesis of the endometrial glands is critical to the gestational capacity of the uterus. Furthermore, disrupted endometrial gland formation in adult mice can result in permanent infertility [18, 19] . Because the AR is also specifically expressed in the endometrial gland epithelia, we therefore aimed to develop (Cre/loxP) and characterize an uterine gland endometrial-specific ARKO (ugeARKO) mouse model. Using the ugeARKO in comparison to ARKO females, we further characterized the role of androgens acting via AR in uterine development and function. In addition, because most endometrial carcinomas originate from glandular epithelia, we further characterized the endometrial glands-specific Cre activity by generating an uterine glandular epithelium-specific PTEN tumor suppressor [20] knockout (ugePTENKO) based on the observation that PTEN inactivation in the uterus induces endometrial cancer in mice [21, 22] .
MATERIALS AND METHODS

Animals
The following mouse lines were used to generate the WT, ARKO, and ugeARKO females: a Tg (Sox2-cre)1Amc (denoted SOX2-Cre) mice (Cre expressed globally; kindly donated by Dr. L Rob, Walter and Eliza Hall Institute, and Professor A McMahon, Harvard University) [23] , a Tg (Pbsncre)20Fwan mice (denoted PBSN-Cre; Cre expressed selectively in prostate epithelial cells; kindly donated by Dr. Fen Wang, Center for Cancer Biology and Nutrition in Houston) [24] , and Ar tm1Jdz (denoted ARflox) mice [25] . In addition, to characterize functional PBSN-Cre activity in endometrial glandular epithelial cells, PBSN-Cre mice were also crossed to Pten tm1Hwu mice (denoted PTENflox) [26] to generate the ugePTENKO, where inactivation of PTEN causes uterine pathologies [22, 27] . All the mice were backcrossed to the FVB/ N background for at least six generations (AR-floxed mouse originally C57BL/ 6 background). ARKO and WT females were generated by crossing SOX2-Cre and ARflox mice, respectively, as previously described [23] . The ugeARKO and ugePTENKO females were generated by crossing the PBSN-Cre and ARflox or PTENflox mice, respectively, with Cre-negative females used as a WT controls as previously described for males [24] . Experimental mice were genotyped as previously described for ARKO [28] and PTENKO mouse models [29] . All the mice were housed under standard conditions (198C-228C, 12L:12D) in cages with ad libitum access to water and food.
Model Validation
Whole mount LacZ staining. To detect functional recombinase activity of a PBSN-Cre in females, PBSN-Cre mice were crossed with Gt (ROSA)26Sor (denoted R26R) [30] . In the R26R mice, Cre mediates activation of a floxedlacZ gene, and the following LacZ activity can be detected by whole mount bgalactosidase staining to localize the Cre activity. Whole mount b-galactosidase staining method has been used in previous studies on mouse uterus [31, 32] .
In brief, dissected tissues from PBSN-Cre/R26R (R26R
Creþ
) and nontransgenic/R26R control (R26R CreÀ ) mice were lightly prefixed in 0.2% glutaraldehyde for 1 h at room temperature, then incubated with 5-bromogalactopyranoside (X-gal; 0.5mg/ml) staining for 4 h at 378C, and washed with PBS, followed by postfixation overnight in 4% paraformaldehyde at 48C. Tissues were paraffin embedded, dewaxed, and 10 lm sections on glass slides counterstained using Nuclear Fast Red (Sigma). To confirm that the positive staining was not due to endogenous cre activity, the PBSN-cre negative tissues were used as negative controls.
Genotype confirmation. Excision of exon 3 of Ar in ARKO and ugeARKO uterus was confirmed on genomic DNA and mRNA level. Genomic DNA was released using proteinase K digestion of the uterus or by a DNA extraction kit (Qiagen DNeasy Blood and Tissue Kit). PCR on genomic DNA was performed as previously described [33] . In addition, excision of exon 3 of Ar in the uterus was confirmed by RT-PCR on the RNA extracted from uteri as previously described [29] . Two product sizes were obtained, 288 bp for intact Ar and 171 bp for Cre-mediated exon 3-excised Ar.
To confirm specific excision of exon 3 of Ar occurs solely in glandular epithelial cells of ugeARKO, genomic DNA was extracted from laser microdissected formalin-fixed paraffin embedded (FFPE) uterus samples. In brief, FFPE uterine sections were sectioned at 15 lm thickness onto membrane slides (MembraneSlide NF 1.0 PEN [D]; Carl Zeiss). Standard hematoxylin and eosin (H&E) staining was performed to visualize glandular epithelial cells. PALM Duoflex Combi System was used for laser capture microdissection. Upon laser microdissection, glandular epithelial cells were captured in adhesive cap (AdhesiveCap 500 opaque [D] ; Carl Zeiss). In addition, laser microdissection was performed to capture nonglandular uterus (i.e., uterus excluding glandular epithelium). Excision of DNA between floxP sites of Ar (exon 3) was confirmed by PCR using the same primers as previously described [34] creating an exon 3-excised Ar at 510 bp. Furthermore, to confirm that functional Ar was still present in nonglandular uterus tissue, PCR using the same primers as for genotyping [28] detected undeleted (floxed) Ar at 280 bp, confirming tissue specificity of Cre activity for glandular and not nonglandular uterus.
Excision of exon 5 in PTENKO was confirmed on genomic DNA. Exon 5 excision of Pten was confirmed by PCR using the same primers as for genotyping [35] . Two product sizes were obtained, 650 bp for intact Pten and 300 bp for Cre-mediated exon 5-excised Pten. b-Actin was used as a loading control. Exon 5 deletion in Pten was not confirmed by RT-PCR using RNA because the Cre-mediated excision of DNA between loxP sites of Pten produces a stop codon and no exons are produced after exon 4 [36] .
Real-time PCR was performed to determine Pbsn mRNA expression in the uterus. Prostate samples were used as a positive control. PBSN PCR was performed as previously described in [37, 38] .
Experimental Design and Tissue Collection
Model characterization. To characterize the uterine specificity of PBSNCre in females, the uterus, ovaries, mammary gland, and pituitary were collected from R26R
Creþ and R26R CreÀ females at 10 and 20 wk of age. In addition, to confirm that the PBSN-Cre mediated excision of tumor suppressor PTEN generates glandular hyperplasia, the ugePTENKO females were collected at 30 wk of age to be subjected to PCR and immunocytochemistry for detection of Cre-mediated recombination. To determine the time of PBSNCre activation, ugePTENKO females were also collected at 3, 6, and 8 wk.
Fertility. To evaluate the effect of endometrial gland-specific AR inactivation on fertility, the 8-to 10-wk-old WT and ugeARKO females were continuously mated with an individual WT male (at least 8-wk-old) for a 5-mo period. Cages were monitored daily, and the number of pups and litters were recorded.
Ovariectomy and implants. To further characterize the androgen action in the uterus, a group of female mice were ovariectomized (OVX) under anesthesia at 5 wk and had 1 cm silastic implants (inner diameter ¼ 1.47 mm and outer diameter ¼ 1.95 mm; Dow-Corning) either containing ;10 mg crystalline testosterone (T) or no steroid placed subdermally for 15 wk and subsequently collected at 20 wk of age. Initially, long-term T treatment was given to allow enough time for the T to show effects on uterine regrowth. To investigate whether the nonaromatizable DHT behaved similarly to T, a second group of female mice were OVX at 8 wk and received silastic implants subdermally containing either T or DHT (23 0.5 cm silastic implant filled with ;5 mg crystalline DHT [37] ) or empty implant for 3 wk with the mice sacrificed for tissue collection at 11 wk of age. Short-term treatment was used based on the findings from our long-term treatment together with our laboratory's previous experiences with DHT treatment of males mice where significant changes occurred within 3 wk of DHT treatment [39] . Intact females were also collected at the age of 11 and 20 wk.
Tissue collection. Female mice were euthanized by cardiac exsanguination under ketamine/xylazine anesthesia. The uteri were dissected and weighed. Organs were fixed in 4% paraformaldehyde at 48C overnight for histological processing. All the experiments and procedures were approved by the Sydney South West Area Health Service Animal Welfare Committee within National Health and Medical Research Council guidelines for animal experimentation.
RNA Extraction, DNase Treatment, cDNA Synthesis, and Quantitative Real-Time RT-PCR These procedures were performed as previously described in [37] . To measure mRNA expression of lactoferrin, complement component 3 (C3), and glucose-6-phosphate dehydrogenase (G6PDH), the following primers were used: lactoferrin-forward (5 0 -CTAACCAGACCAGATCCTGCA-3 0 ) and lactoferrin-reverse
. Target gene expressions were normalized to internal housekeeping gene, mouse ribosomal protein (Rpl19), as previous described [40] . To determine the ontogeny of PBSN-Cre in the uterus, mRNA expression of Cre was also measured using these primers: Cre-forward (5 0 TGCCAGGATCAGGGTTAAAG-3 0 ) and Crereverse (5 0 -ACACCAGAGACGGAAATCCA-3 0 ).
Histology and Histomorphological Analyses
The midsection from a fixed uterine horn was embedded in paraffin, sectioned at 5 lm, and stained with standard H&E procedures for histological analyses. Using light microscopy, different areas of uterine section were marked (total area, myometrium, endometrium, and lumen), and each area was calculated using CASTGRID software (Olympus). Measurements were repeated on three different uterine sections for each sample, and the measurements were averaged.
Immunohistochemistry
PTEN immunolocalization was performed in paraffin-embedded uterine sections (5 lm) using PTEN antibody (138G6, dilution 1:50; Cell Signaling Technology) and a Vectastain Elite ABC Kit (Vector Laboratories). Citric acid CHOI ET AL.
(10 mM, pH 6) was used for antigen retrieval. Pierce Superblock (containing 0.5% bovine serum albumin; Thermo Scientific) was used as the blocking solution.
Hormone Assays
Testosterone, dehydroepiandrosterone (DHEA), DHT, estrone (E 1 ), and E 2 levels were measured in extracts of 100 ll mouse serum by liquid chromatography tandem mass spectrometry (LC-MS/MS) [41] as modified for mouse serum [42] . The lowest limits of quantification (defined as detectable with coefficient of variation ,20%) were 10 pg/ml for T, 20 pg/ml for DHEA, 50 pg/ml for DHT, 2.5 pg/ml for E 2 , and 1 pg/ml for E 1 .
Statistical Analysis
Statistics were performed by one-way ANOVA with the least significant difference method as a post hoc test using SPSS software (SPSS, Inc.) unless specified otherwise. P values smaller than 0.05 were considered statistically significant.
RESULTS
Successful Generation and Validation of Endometrial
Gland-Specific ARKO Mouse Model PBSN-Cre mice are generally used to direct the Cre expression selectively into prostate epithelial cells [29] . However, unexpectedly, we observed possible uterine-specific expression in female mice, and we, therefore, further pursued validating the PBSN-Cre mouse model for uterine-specific Cre expression. This was achieved by localizing the Cre activity in female mice. PBSN-Cre mice were crossed with R26R mouse. Tissues were collected at two different time points, at 10 and 20 wk of age. Cre activity was analyzed in uterus, ovary, mammary gland, and pituitary of both the 10 and 20 wk of age. Blue lacZ staining was only detected in the glandular epithelial cells of the uterus (Fig. 1, A and B) . No staining was detected in the Cre-negative uterus (Fig. 1C) . Ovary, mammary gland, and pituitary (Fig. 1, D-F) were all negative for lacZ staining. Morphology of Cre-positive and -negative uterus is shown in Figure 1 , G and H.
PCR was used to confirm SOX2-Cre and PBSN-Cre mediated excision of exon 3 of Ar in ARKO and ugeARKO uterus. Only native and exon 3-deleted Ar RT-PCR product were detected in WT and ARKO uterus, respectively. Due to uterine glandular epithelial cell-specific Cre activity, the ugeARKO uterus showed weak exon 3-deleted Ar product (glandular epithelial cells) and strong native Ar PCR product (nonglandular uterine cells) (Fig. 1I) . Similar to the WT ovaries, the ovaries of ugeARKO females only expressed native Ar (Fig. 1I) .
Furthermore, laser microdissection was performed to confirm that excision of exon 3 of Ar in ugeARKO uterus is specific to the glandular epithelial cells (Fig. 1, J and K) . Exon 3-deleted Ar PCR product was only detected in glandular cells of ugeARKO uterus (Fig. 1L ) whereas undeleted (floxed) Ar PCR product was detected solely in the nonglandular tissue of the uterus in ugeARKO mice (Fig. 1M) .
Similarly, PCR was used to confirm PBSN-Cre mediated excision of exon 5 of Pten in the ugePTENKO uterus. Due to uterine glandular epithelial cell-specific Cre activity, the ugePTENKO uterus showed weak exon 5-deleted Pten product (glandular epithelial cells) and strong native Pten PCR product (nonglandular epithelial cells) (Fig. 1N) . Similar to the WT ovaries, the ovaries of ugePTENKO females only expressed native Pten (Fig. 1N) . To further confirm the gland specificity of PBSN-Cre activity, PTEN immunohistochemistry was performed in WT and ugePTENKO uterus. Uterine glands were strongly PTEN immunopositive in WT uterus (Fig. 1O) but were negative for PTEN immunostaining in ugePTENKO uterus (Fig. 1P) . The negative control did not show any PTEN immunostaining in the uterus (Fig. 1Q) .
Furthermore, to determine the age dependency of PBSN-Cre activation, the Pten PCR was performed on uteri at 3, 6, and 8 wk of age. Exon 5-deleted Pten product was only detected at 8 wk of age but not earlier ( Fig. 2A) , showing that PBSN-Cre is activated after 6 wk of age but before 8 wk. In addition, we measured Cre mRNA expression to determine the ontogeny of PBSN-Cre in uterus. The result shows that Cre was only detected at 8 wk of age but not at 6 or 3 wk (Fig. 2B) , further supporting the finding that PBSN-Cre is activated between 6 and 8 wk.
To further validate the functional PBSN-Cre activity in ugePTENKO mice, uterine weights and morphology were compared between WT and ugePTENKO females. The uterine weight of ugePTENKO was significantly increased compared to WT females (Fig. 3A) . Macroscopic analysis of ugePTEN-KO uterus demonstrated a clearly abnormal uterus compared to WT (Fig. 3, B and C) . Histological analysis of ugePTENKO uterus suggested that the increased weight and abnormal appearance was due to the presence of hyperplastic and neoplastic uterine glands in ugePTENKO uterus not present in WT uteri (Fig. 3, D-F) . Pbsn mRNA was not detectable in our uterine samples at the age of 20 wk by real-time PCR (Supplement Fig. S1 ; Supplemental Data are available online at www.biolreprod.org).
Endometrial Gland-Specific AR Inactivation Does Not Modify Uterine Growth or Function (Fertility)
No significant differences in uterine weight were detected between WT females from ARKO or ugeARKO colonies (Supplemental Fig. S2) , and therefore the data from both WT female lines were combined. The uterine weights were similar between WT, ARKO, and ugeARKO females at 20 wk of age (Table 1) . Also, there were no changes in histomorphometric measurements such as total uterine area or endometrial and myometrial area ( Table 1) .
Fertility of WT and ugeARKO females was compared by determining the number of pups per litter and total number of pups produced by the female over a 5-mo period. No difference in pups per litter was observed between WT and ugeARKO females where both produced approximately 11 pups per litter (Fig. 4A) . Also, total number of pups produced over a 5-mo period for each female did not differ between WT and ugeARKO, both groups producing approximately 50 pups over 5-mo period (Fig. 4B) . This suggests that inactivation of endometrial glandular epithelial AR did not affect fertility of female mice between 8 wk to 5 mo of age.
AR-Mediated Androgen Actions Are Required for TInduced Uterine Growth
As expected, OVX at 5 wk of age prevented normal uterine growth in all females with the uterine weights in the OVX groups being about 15% of the intact female uterine weights at 20 wk of age (Fig. 5A) . In WT females, T treatment following OVX (OVXþT) fully restored the uterine weight to the intact level at 20 wk of age (Fig. 5A) . However, no uterine growth was detected following OVX and T treatment in ARKO females, and the uterus weight remained similar to OVX-only females (Fig. 5A) , suggesting that AR-mediated T effects are required for uterine growth. Interestingly, OVXþT treatment of ugeARKO females resulted in partial restoration (approx- imately 50%) of uterine weights when compared to intact ugeARKO uterus weights (Fig. 5A) .
Endometrial Glandular AR Modifies T-Induced Uterine Growth (Both in the Endometrium and Myometrium)
Morphological measurements, notably total, endometrial, and myometrial areas, were measured in the uterus. However, these measurements could not be made in the OVX group and OVXþT treated ARKO because these uteri were too underdeveloped to make these measurements accurately (Fig.  5, B-D) . The OVX group (Fig. 5 , K and L) had similar histological appearances to the OVXþT treated ARKO uteri (Fig. 5, G and H) .
OVXþT treated WT uterus had full regrowth of all the areas (endometrial and myometrial areas) and they were similar to the WT intact (Fig. 5, B-D) . Uterine areas (total, endometrial, and myometrial) of OVXþT treated ugeARKO were approximately 50% of OVXþT treated WT uterus (Fig. 5, B-D) . This suggests that endometrial glandular epithelial AR plays a role in the uterine development modifying not only the endometrium but the myometrium as well. This results in the maintenance of a stable endometrium to myometrium ratio such that both the WT and ugeARKO in the OVXþT group had a similar endometrium to myometrium ratio (Supplement Fig. S3 ). Representative figures of each OVXþT treated uterus are shown in Figure 5 , E-L.
Androgens Alone Can Promote Full Uterine Regrowth and Do Not Require E 2 in Mice
Because T can be aromatized into E 2 via aromatase activity, we used a nonaromatizable androgen, DHT, to determine if the AR-mediated androgen effect on uterine growth requires E 2 .
FIG. 2. Ontogeny of PBSN-Cre in uterus.
A) PTEN PCR has been conducted at 3-, 6-, and 8-wk-old uteri and ovaries to show time of PBSN-Cre activation in the uterus. Exon 5-deleted PTEN band (300 bp) was only present at 8-wk-old uterus but not in other time points. Hence, the data indirectly shows that Pbsn-Cre is active at 8-wk-old uteri but not in ovaries. B) Real-time RT-PCR was performed to compare Cre mRNA expression at 3-, 6-, 8-, and 20-wk-old ugePTENKO uterus samples (n ¼ 2 for each time point). Water was used as negative control. Uterus samples at 20 wk show exponential increase in fluorescence at around 25 cycles compared to negative control with increased fluorescence at 45 cycles. Uterine samples at 8 wk of age show fluorescence at around 35 cycles whereas uterine samples at 3 and 6 wk of age show fluorescence at the same cycle as negative control. This shows that PBSN-Cre is not expressed at 3 and 6 wk of age in the uterus. (Table 1) were compared between WT, ARKO, and ugeARKO females at 20 wk of age. In addition, the fertility (pups per litter, cumulative pups) was compared between ugeARKO and WT females (A, B) . Data are shown as mean 6 SEM (n ! 4).
AR-MEDIATED ANDROGEN ACTION IN THE UTERUS
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Intact WT and ARKO uterine weights were similar, while the OVX group at 11 wk of age (OVX at 8 wk old) significantly reduced (P , 0.05, nonparametric test) uterine weights in both WT and ARKO (Fig. 6A ). Both T and DHT treatment at the time of OVX for 3 wk restored the uterine weights to the intact level in WT but had no effect on uterine weights in ARKO females. This finding suggests that androgens (testosterone and DHT) alone acting via AR can promote full uterine regrowth in the absence of E 2 (Fig. 6A) .
Treatment Protocols Produced Supraphysiological Serum Levels of T and DHT
To determine if the intact female mouse serum T and DHT levels were comparable to those produced by the steroid hormone implants used in the present study, serum T, DHT, DHEA, E 1 , and E 2 levels were determined using LC-MS/MS. Serum T was 20-fold higher (P 0.05; nonparametric test) in OVXþT treated compared to intact WT and ARKO females, suggesting that T implant produced supraphysiological T levels (Fig. 6B) . In addition, OVX reduced serum T levels when compared to intact females. Serum DHT levels were increased 8-and 36-fold in the OVXþDHT treated group compared to intact WT and ARKO females, respectively, demonstrating that DHT implants also produced supraphysiological DHT levels (Fig. 6C) . Unexpectedly, serum DHT was significantly higher in OVXþDHT treated ARKO females compared to OVXþDHT treated WT females despite the similarity of the implants used. Serum DHT was also increased in OVXþT treated WT females (compared to intact and OVX) but not in ARKO, suggesting significant conversion of T to DHT in WT but not in ARKO females. Serum DHEA, E 1 , and E 2 were below the assay detection limits.
AR-MEDIATED ANDROGEN ACTION IN THE UTERUS
Testosterone and DHT via AR-Induced Uterine Regrowth in WT Uterus and AR and Estrogen Receptor May Share the Same Signaling Pathway (Lactoferrin)
To determine if androgen-induced uterine regrowth was via AR and if AR and estrogen receptor (ER) share a signaling pathway, we investigated the ERa-dependent Lactoferrin mRNA expression (Fig. 6D) . As expected, ovariectomy in WT and ARKO significantly reduced (P , 0.05) lactoferrin expression compared to the intact groups. Lactoferrin expression was significantly increased in OVXþT and OVXþDHT groups compared to OVX alone in WT (which was comparable to WT intact) but there were no changes in ARKO, suggesting that androgen-induced uterine regrowth was via AR. Furthermore, AR and ER may share same signaling pathway. Surprisingly, in intact females, lactoferrin expression was significantly increased (P , 0.05, nonparametric test) in the ARKO uterus compared to the WT uterus. Similar expression patterns were observed in C3 and G6PDH (Supplemental Fig.  S4 ).
DISCUSSION
AR is expressed in the mouse [2, 3] and human [4] uterus, and direct androgen actions via AR has been suggested to regulate uterine physiology and growth [43] . In the mouse, AR is abundantly expressed throughout the uterus, including in the endometrial glands [2] . We therefore explored the role of androgens via the AR in experimental uterine development and, for the first time, generated and characterized an endometrial gland-specific knockout mouse model to investigate the role of endometrial gland-specific AR in uterine development and fertility. Our discovery that the PBSN-Cre directs selective endometrial gland expression of Cre may be of value in future experimental research into uterine physiology and pathology.
To determine the role of AR-mediated, endogenous androgen actions in murine uterus development, we compared uterus weights and uterine structure between sexually mature WT, ugeARKO, and ARKO females. AR inactivation in either endometrial glands or globally did not significantly modify uterine weights or uterine structure in our study. Similarly, in our previous study, uterine weights were similar between WT and ARKO females whereas the total, endometrial, and myometrial uterine areas were significantly reduced in ARKO when compared to 8-wk-old WT females [11] . While the model of AR inactivation between the studies is similar, the discrepancy in the affected uterine areas between the previous and present studies could be due to the different age and genetic background of the mice. Uterine function (as indicated by fertility) appeared to be unaffected by endometrial gland- 
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specific AR inactivation because the number of pups per litter and total number of pups over a 5-mo mating study were similar between ugeARKO and WT females. Although there are no studies suggesting the role of endometrial gland AR inactivation in fertility, our previous study has shown that global AR inactivation significantly reduced fertility by 60% compared to the control group [11] . Despite endometrial glands synthesizing essential substances for survival and development of the embryo [44] , our study suggested that the lack of endogenous androgen actions via the endometrial gland AR does not have a significant effect on uterine development and fertility in mice, presumably due to redundancies in molecular pathways to provide this essential support for embryo developmental.
However, because androgens are suggested to support uterine growth [8, 9] , we further investigated the role of global AR and endometrial gland-specific AR inactivation by removing ovarian steroids (estrogens, progesterone) by ovariectomy and administering a T implant. As expected, ovariectomy reduced uterine weights to about 15% of intact weights without any significant difference among the genotypes. On the other hand, while WT uterus displayed full regrowth to intact weights upon T treatment after ovariectomy, the ARKO uterus displayed no regrowth and uterine weights remained at the OVX level, demonstrating that AR-mediated androgen action alone can fully support uterine regrowth following ovariectomy.
In addition, we show that the growth-promoting effects of androgens are via AR present in uterus because the ugeARKO females showed only 50% regrowth of the uterus following ovariectomy and T treatment. This suggests a significant role of endometrial gland-specific AR in androgen effects on uterine regrowth following ovariectomy. The 50% regrowth is striking because uterine glands constitute only ,5% of the uterine structure. Hence, AR activity in the endometrial uterine glands affects the myometrium, suggesting AR-mediated paracrine signaling between the endometrial and myometrial cells.
Because estrogens may modify androgen actions [2] and uterine function is estrogen dependent, we further explored if the T conversion to E 2 is required in AR-mediated androgen effects on uterine regrowth. Using the nonaromatizable androgen DHT, we observed full restoration of uterine growth in WT females whereas the ARKO uterus had no regrowth, remaining similar to the estrogen-deficient uterus. This further supports our finding that androgens acting via AR alone can promote full uterine regrowth without requiring E 2 . This could be due to AR and ERa sharing similar molecular pathways as demonstrated by the finding that androgens (T and DHT) acting via AR (lack of induction in ARKO) induced expression of the ERa-dependent genes lactoferrin, C3, and G6PDH. However, the ERa knockout (ERaKO) and aromatase knockout (ArKO) female mice with supraphysiological levels of circulating T lacked uterine growth, suggesting the essential role of E 2 in normal peripubertal uterine growth and development in mice [45] [46] [47] . In addition, although we expect E 2 to be absent in the OVX mice and E 2 was under the detection limit (2.5 pg/ml) of LC-MS/MS, we must consider the phytoestrogens that may be present through the diet and may play a role in uterine regrowth because a high phytoestrogen diet elevated estrogen-dependent genes in mice [48, 49] .
In our ugeARKO model, the floxed Ar gene creates a highly selective deletion of only exon 3 (the second zinc finger of the DNA-binding domain) of the AR. This creates a minimally truncated AR that is fully inactivated but is much closer to physiological than the major deletions of the AR protein created by introducing stop codons early into the translated protein. Unfortunately, the flip side of such highly selective, minimal deletion from a large protein is that it has proved impossible to obtain commercially available or customgenerated antibodies specific to the truncated exon 3-deleted AR. Hence, AR protein was detected by all commercial N-and C-terminal antibodies as well as any custom antibodies we tried to generate. However, although the AR protein remains present immunohistochemically in its mutated form, it is functionally inactive [33] . Hence, as an alternative to proving the cellularspecificity of the Cre-mediated excision of exon 3, we microdissected uterine glandular epithelium from ugeARKO uterus and confirmed that the exon 3-deleted, inactive AR is only present in the glands of ugeARKO uterus with no functional (undeleted) Ar being detected in the glands of the ugeARKO uterus. Conversely, nonglandular uterine tissue expressed only the undeleted Ar.
We further validated and characterized the functional Cre activity in endometrial glands using the ugePTENKO mouse model. Pten is a tumor suppressor gene [20] , and knockout of PTEN causes endometrial cancer in mice [21, 22] . First, we demonstrated that PBSN-Cre activity is only present in endometrial glands by PTEN immunolocalization, where only the endometrial glands of ugePTENKO uterus were PTEN immunonegative compared to PTEN-immunopositive glands in WT. Second, by measuring PTEN deletion and Cre mRNA expression, we have demonstrated that PBSN-Cre is only present in 8 wk of age but not at 3 and 6 wk. Hence, the ontogeny of PBSN-Cre in mouse uterus is between 6 and 8 wk of age. Third, to demonstrate functional consequence of PTEN deletion in the uterine glands, we showed significantly increased uterine weight in ugePTENKO females with the presence of abnormal morphology and uterine histopathology not present in WT. Because the PTEN-deletion mouse model has been widely used in uterine cancer research [21, 22] , our model would be a novel model to investigate uterine cancer because it has been suggested that adenocarcinoma in uterus arises from endometrial glands [50] . Hence, the model would provide a new platform for future uterine cancer research.
To create the endometrial gland-specific knockout, we used the PBSN-Cre mouse line for the Cre/loxP system. PBSN is a prostate-specific protein that has been used to generate prostate-specific genetically modified mouse models [29] . Surprisingly, we have shown that the PBSN-Cre mouse line [24] can also be used to generate uterine gland-specific knockouts in females. Although, Pbsn mRNA was not detectable in our uterine samples at 20 wk diestrus, it is possible that Pbsn may be expressed earlier during uterine development, it may be dependent on the estrous cycle, or the expression generated using the PBSN promoter is specific for this PBSN-Cre model under the control of an unknown mechanism [24] . Also, we have shown that Pbsn is selectively active in glandular epithelial cells in the uterus. Hence, the PBSN-Cre mouse line [24] used can effectively generate uterine gland-specific knockout mice.
While other mouse models are also available to generate knockouts in the uterus, including endometrial knockouts using a progesterone receptor (PR)-cre mouse line [51] or conditional gene recombination by adenovirus-driven cre [52] , these mice have some disadvantages. The disadvantage of the PR-cre mouse line is that PR is also expressed in other tissues such as the pituitary, ovary, and mammary gland [51] that, depending on the knockout target, could have systemic effects, including changes in the hormone profile, hence effecting uterine physiology. The disadvantage of the adenovirus-driven cre model is the difficulty the recombination strategy has in AR-MEDIATED ANDROGEN ACTION IN THE UTERUS controlling the amount and localization of cre delivered by the adenovirus vector. This may result in high variability in the amount and localization of knockout between individual experimental mice.
In conclusion, we have demonstrated that androgens acting solely via AR can support full uterine growth. Furthermore, we have generated and characterized the first endometrial glandspecific genetically modified mouse model, and using the model, we have shown that endometrial gland AR mediates uterine (including myometrial) growth via AR-mediated androgen actions. These findings warrant further investigations into the role of the AR and the cross talk involving AR expression in different types of uterine cells such as luminal, stromal, and myometrial cells. Also, the role of endometrial gland AR should be investigated in uterine disorders such as endometrial cancer, which could lead to better biomarkers and more effective novel treatment of uterine disorders.
